Rhythm Pharmaceuticals (RYTM) Upgraded at BidaskClub

Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a report released on Tuesday.

Several other equities research analysts have also commented on RYTM. Bank of America assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $30.00 target price on the stock. Cowen restated a “buy” rating and set a $40.00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Finally, Morgan Stanley assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 30th. They issued an “equal weight” rating and a $23.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $31.25.

Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) opened at $29.04 on Tuesday. Rhythm Pharmaceuticals has a 1 year low of $21.38 and a 1 year high of $33.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Tuesday, November 14th. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.40) by ($1.38). equities research analysts predict that Rhythm Pharmaceuticals will post -1.63 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Rhythm Pharmaceuticals (RYTM) Upgraded at BidaskClub” was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.com-unik.info/2018/01/23/rhythm-pharmaceuticals-rytm-upgraded-at-bidaskclub.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit